Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics
10.1038/sj.leu.2403366
Crossref journal-article
Springer Science and Business Media LLC
Leukemia (297)
Bibliography

Roche, J., Zeng, C., Barón, A., Gadgil, S., Gemmill, R. M., Tigaud, I., Thomas, X., & Drabkin, H. A. (2004). Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics. Leukemia, 18(6), 1059–1063.

Authors 8
  1. J Roche (first)
  2. C Zeng (additional)
  3. A Barón (additional)
  4. S Gadgil (additional)
  5. R M Gemmill (additional)
  6. I Tigaud (additional)
  7. X Thomas (additional)
  8. H A Drabkin (additional)
References 40 Referenced 45
  1. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333. (10.1182/blood.V92.7.2322) / Blood by D Grimwade (1998)
  2. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320. (10.1182/blood.V98.5.1312) / Blood by D Grimwade (2001)
  3. Greer JM, Puetz J, Thomas KR, Capecchi MR . Maintenance of functional equivalence during paralogous Hox gene evolution. Nature 2000; 403: 661–665. (10.1038/35001077) / Nature by JM Greer (2000)
  4. Borrow J, Shearman AM, Stanton Jr VP, Becher R, Collins T, Williams AJ et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet 1996; 12: 159–167. (10.1038/ng0296-159) / Nat Genet by J Borrow (1996)
  5. Fujino T, Suzuki A, Ito Y, Ohyashiki K, Hatano Y, Miura I et al. Single-translocation and double-chimeric transcripts: detection of NUP98-HOXA9 in myeloid leukemias with HOXA11 or HOXA13 breaks of the chromosomal translocation t(7;11)(p15;p15). Blood 2002; 99: 1428–1433. (10.1182/blood.V99.4.1428) / Blood by T Fujino (2002)
  6. La Starza R, Trubia M, Crescenzi B, Matteucci C, Negrini M, Martelli MF et al. Human homeobox gene HOXC13 is the partner of NUP98 in adult acute myeloid leukemia with t(11;12)(p15;q13). Genes Chromosomes Cancer 2003; 36: 420–423. (10.1002/gcc.10182) / Genes Chromosomes Cancer by R La Starza (2003)
  7. Panagopoulos I, Isaksson M, Billstrom R, Strombeck B, Mitelman F, Johansson B . Fusion of the NUP98 gene and the homeobox gene HOXC13 in acute myeloid leukemia with t(11;12)(p15;q13). Genes Chromosomes Cancer 2003; 36: 107–112. (10.1002/gcc.10139) / Genes Chromosomes Cancer by I Panagopoulos (2003)
  8. Taketani T, Taki T, Ono R, Kobayashi Y, Ida K, Hayashi Y . The chromosome translocation t(7;11)(p15;p15) in acute myeloid leukemia results in fusion of the NUP98 gene with a HOXA cluster gene, HOXA13, but not HOXA9. Genes Chromosomes Cancer 2002; 34: 437–443. (10.1002/gcc.10077) / Genes Chromosomes Cancer by T Taketani (2002)
  9. Taketani T, Taki T, Shibuya N, Kikuchi A, Hanada R, Hayashi Y . Novel NUP98-HOXC11 fusion gene resulted from a chromosomal break within exon 1 of HOXC11 in acute myeloid leukemia with t(11;12)(p15;q13). Cancer Res 2002; 62: 4571–4574. / Cancer Res by T Taketani (2002)
  10. Taketani T, Taki T, Shibuya N, Ito E, Kitazawa J, Terui K et al. The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11)(q31;p15). Cancer Res 2002; 62: 33–37. / Cancer Res by T Taketani (2002)
  11. Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD . NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res 1998; 58: 4269–4273. / Cancer Res by SZ Raza-Egilmez (1998)
  12. Nakamura T, Largaespada DA, Shaughnessy Jr JD, Jenkins NA, Copeland NG . Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet 1996; 12: 149–153. (10.1038/ng0296-149) / Nat Genet by T Nakamura (1996)
  13. Ayton PM, Cleary ML . Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 2003; 17: 2298–2307. (10.1101/gad.1111603) / Genes Dev by PM Ayton (2003)
  14. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L et al. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 2002; 16: 186–195. (10.1038/sj.leu.2402354) / Leukemia by HA Drabkin (2002)
  15. Thompson A, Quinn MF, Grimwade D, O'Neill CM, Ahmed MR, Grimes S et al. Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by small-array real-time PCR. Blood 2003; 101: 1558–1565. (10.1182/blood.V101.4.1558) / Blood by A Thompson (2003)
  16. Debernardi S, Lillington DM, Chaplin T, Tomlinson S, Amess J, Rohatiner A et al. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 2003; 37: 149–158. (10.1002/gcc.10198) / Genes Chromosomes Cancer by S Debernardi (2003)
  17. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752–1759. (10.1182/blood.V98.6.1752) / Blood by PD Kottaridis (2001)
  18. Bennett JM, Cato D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–625. (10.7326/0003-4819-103-4-620) / Ann Intern Med by JM Bennett (1985)
  19. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336. (10.1182/blood-2002-03-0772) / Blood by JC Byrd (2002)
  20. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717–2723. (10.1182/blood-2002-03-0990) / Blood by C Preudhomme (2002)
  21. Wodnar-Filipowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C . Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood 1996; 88: 4493–4499. (10.1182/blood.V88.12.4493.bloodjournal88124493) / Blood by A Wodnar-Filipowicz (1996)
  22. Haidar JH, Bazarbachi A, Mahfouz R, Haidar HA, Jaafar H, Daher R . Serum Flt3 ligand variation as a predictive indicator of hematopoietic stem cell mobilization. J Hematother Stem Cell Res 2002; 11: 533–538. (10.1089/15258160260090997) / J Hematother Stem Cell Res by JH Haidar (2002)
  23. Crooks GM, Fuller J, Petersen D, Izadi P, Malik P, Pattengale PK et al. Constitutive HOXA5 expression inhibits erythropoiesis and increases myelopoiesis from human hematopoietic progenitors. Blood 1999; 94: 519–528. (10.1182/blood.V94.2.519.414k20_519_528) / Blood by GM Crooks (1999)
  24. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G . Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol 2001; 21: 224–234. (10.1128/MCB.21.1.224-234.2001) / Mol Cell Biol by U Thorsteinsdottir (2001)
  25. Sauvageau G, Thorsteinsdottir U, Hough MR, Hugo P, Lawrence HJ, Largman C et al. Overexpression of HOXB3 in hematopoietic cells causes defective lymphoid development and progressive myeloproliferation. Immunity 1997; 6: 13–22. (10.1016/S1074-7613(00)80238-1) / Immunity by G Sauvageau (1997)
  26. Antonchuk J, Sauvageau G, Humphries RK . HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation. Exp Hematol 2001; 29: 1125–1134. (10.1016/S0301-472X(01)00681-6) / Exp Hematol by J Antonchuk (2001)
  27. Kyba M, Perlingeiro RC, Daley GQ . HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002; 109: 29–37. (10.1016/S0092-8674(02)00680-3) / Cell by M Kyba (2002)
  28. Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kahls P, Mitterbauer G et al. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 2004; 18: 293–302. (10.1038/sj.leu.2403243) / Leukemia by A Weltermann (2004)
  29. Hanson RD, Hess JL, Yu BD, Ernst P, van Lohuizen M, Berns A et al. Mammalian Trithorax and polycomb-group homologues are antagonistic regulators of homeotic development. Proc Natl Acad Sci USA 1999; 96: 14372–14377. (10.1073/pnas.96.25.14372) / Proc Natl Acad Sci USA by RD Hanson (1999)
  30. Beuchle D, Struhl G, Muller J . Polycomb group proteins and heritable silencing of Drosophila Hox genes. Development 2001; 128: 993–1004. (10.1242/dev.128.6.993) / Development by D Beuchle (2001)
  31. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173–183. (10.1016/S1535-6108(03)00003-5) / Cancer Cell by SA Armstrong (2003)
  32. Bilder D, Graba Y, Scott MP . Wnt and TGFbeta signals subdivide the AbdA Hox domain during Drosophila mesoderm patterning. Development 1998; 125: 1781–1790. (10.1242/dev.125.9.1781) / Development by D Bilder (1998)
  33. Maloof JN, Whangbo J, Harris JM, Jongeward GD, Kenyon CA . Wnt signaling pathway controls hox gene expression and neuroblast migration in C elegans. Development 1999; 126: 37–49. (10.1242/dev.126.1.37) / Development by JN Maloof (1999)
  34. McWhirter JR, Neuteboom ST, Wancewicz EV, Monia BP, Downing JR, Murre C . Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia. Proc Natl Acad Sci USA 1999; 96: 11464–11469. (10.1073/pnas.96.20.11464) / Proc Natl Acad Sci USA by JR McWhirter (1999)
  35. McWhirter JR, Goulding M, Weiner JA, Chun J, Murre C . A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. Development 1997; 124: 3221–3232. (10.1242/dev.124.17.3221) / Development by JR McWhirter (1997)
  36. Bertho JM, Chapel A, Loilleux S, Frick J, Aigueperse J, Gorin NC et al. CD135 (Flk2/Flt3) expression by human thymocytes delineates a possible role of FLT3-ligand in T-cell precursor proliferation and differentiation. Scand J Immunol 2000; 52: 53–61. (10.1046/j.1365-3083.2000.00746.x) / Scand J Immunol by JM Bertho (2000)
  37. Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003; 101: 3164–3173. (10.1182/blood-2002-06-1677) / Blood by M Mizuki (2003)
  38. Pineault N, Helgason CD, Lawrence HJ, Humphries RK . Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. Exp Hematol 2002; 30: 49–57. (10.1016/S0301-472X(01)00757-3) / Exp Hematol by N Pineault (2002)
  39. Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE . Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 1999; 13: 687–698. (10.1038/sj.leu.2401410) / Leukemia by H Kawagoe (1999)
  40. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531–537. (10.1126/science.286.5439.531) / Science by TR Golub (1999)
Dates
Type When
Created 21 years, 4 months ago (April 15, 2004, 7:09 a.m.)
Deposited 3 years, 5 months ago (March 31, 2022, 9:42 p.m.)
Indexed 5 days, 11 hours ago (Aug. 30, 2025, 1:17 p.m.)
Issued 21 years, 4 months ago (April 15, 2004)
Published 21 years, 4 months ago (April 15, 2004)
Published Online 21 years, 4 months ago (April 15, 2004)
Published Print 21 years, 3 months ago (June 1, 2004)
Funders 0

None

@article{Roche_2004, title={Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics}, volume={18}, ISSN={1476-5551}, url={http://dx.doi.org/10.1038/sj.leu.2403366}, DOI={10.1038/sj.leu.2403366}, number={6}, journal={Leukemia}, publisher={Springer Science and Business Media LLC}, author={Roche, J and Zeng, C and Barón, A and Gadgil, S and Gemmill, R M and Tigaud, I and Thomas, X and Drabkin, H A}, year={2004}, month=apr, pages={1059–1063} }